CULLINAN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PLANNED REGISTRATIONAL PHASE 2 STUDY OF CLN-049 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Reuters · 2d ago

Please log in to view news